WuXi Biologics to Expand to 300 IND Programs a Year by 2027
Image
Basel – October 19, 2026 -- WuXi Biologics will expand annual capacity to approximately 300 IND programs and 20 BLA programs by 2027, as bispecific antibodies and ADCs made up 71% of the 169 projects it added in the first half of 2026. More than two-thirds of those new programs originated in the United States and Europe, the company said at its 3rd annual Basel CRDMO+ Day, held alongside Festival of Biologics Basel 2026, which drew more than 3,000 industry professionals.
The company's portfolio stands at 1,064 integrated projects, including 399 first-in-class programs, 732 global IND clearances and more than 90 market authorizations. More than 100 biotech and pharma leaders attended the Basel session.